A pilot study of the effect of rivaroxaban in sickle cell anemia

CONCLUSIONS: Rivaroxaban was safe but did not significantly decrease coagulation activation, endothelial activation, or inflammation. Rivaroxaban did not improve microvascular blood flow. Adequately powered studies are required to further evaluate the efficacy of rivaroxaban in SCD. Clinicaltrials.gov Identifier: NCT02072668.PMID:33660875 | DOI:10.1111/trf.16343

Source: Transfusion - March 4, 2021 Category: Hematology Authors: Kenneth I Ataga Laila Elsherif David Wichlan Adane F Wogu Neil Matsui Rafal Pawlinski Jianwen Cai Nigel S Key Source Type: research